War Against HSWar Against HS
Drug Pipeline Tracker

HS Drug Pipeline

A comprehensive view of every HS treatment in development - from approved biologics to early-phase candidates. Updated monthly.

DISCLAIMER: This content is for informational and educational purposes only. It is NOT medical advice. Always consult a qualified healthcare professional before making any treatment decisions. Discuss all treatments and clinical trial opportunities with your physician.

3
Approved
1
NDA Filed
0
Phase 3
7
Phase 2

Approved (3)

ApprovedBiologic

Adalimumab(Humira)

Mechanism: TNF-alpha inhibitor
Developer: AbbVie

First FDA-approved biologic for HS (2015)

ApprovedBiologic

Secukinumab(Cosentyx)

Mechanism: IL-17A inhibitor
Developer: Novartis

Approved US & EU 2023

ApprovedBiologic

Bimekizumab(Bimzelx)

Mechanism: IL-17A/IL-17F dual inhibitor
Developer: UCB

Approved US & EU 2024; 3-year data presented EHSF 2026

NDA Filed (1)

NDA FiledSmall Molecule

Povorcitinib

Mechanism: JAK1 inhibitor (oral)
Developer: Incyte

EU filed 2025; US filing expected 2026. First potential oral HS therapy.

Phase 2 (7)

Phase 2Biologic

Sonelokimab

Mechanism: IL-17A/F nanobody
Developer: MoonLake Immunotherapeutics

Recruiting; data expected 2027

Phase 2Biologic

Brivekimig

Mechanism: TNF + OX40L bispecific nanobody
Developer: Sanofi

Positive Phase 2a results at EADV 2025

Phase 2Small Molecule

INF904

Mechanism: C5aR1 antagonist (oral)
Developer: InflaRx

Phase 2a data posted; first complement inhibitor in HS

Phase 2Biologic

Spesolimab

Mechanism: IL-36R inhibitor
Developer: Boehringer Ingelheim

Recruiting; data expected 2026

Phase 2Small Molecule

Orismilast

Mechanism: PDE-4 inhibitor (oral)
Developer: Union Therapeutics

Active, not recruiting; results expected late 2026

Phase 2Small Molecule

Zunsemetinib

Mechanism: MK2 inhibitor (oral)
Developer: Zura Bio

Early Phase 2

Phase 2Biologic

AVTX-002

Mechanism: LIGHT inhibitor
Developer: Avalo Therapeutics

Early Phase 2